$2.01
-0.02 (-0.99%)
Open$2.04
Previous Close$2.03
Day High$2.04
Day Low$2.00
52W High$4.09
52W Low$1.37
Volume—
Avg Volume92.6K
Market Cap77.90M
P/E Ratio—
EPS$-0.67
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,586.1% upside
Current
$2.01
$2.01
Target
$33.89
$33.89
$29.33
$33.89 avg
$54.04
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 71.2K | 106.4K | 14.53M |
| Net Income | -28,055,217 | -37,719,891 | -1,603,701 |
| Profit Margin | -39,417.3% | -37,446.4% | -11.0% |
| EBITDA | -31,250,639 | -44,350,324 | -1,702,906 |
| Free Cash Flow | — | — | -884,905 |
| Rev Growth | -33.1% | -33.1% | +22.5% |
| Debt/Equity | — | — | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.03 | -0.25% | 139.7 | 43.84B |